微波消融联合肝动脉栓塞化疗治疗肝癌46例分析  

Clinical study on microwave ablation combined with transcatheter arterial chemoembolization in treating 46 cases of primary hepatocellular carcinoma

作　　者：郑爱民[1] 叶欣[1] 杨霞[1] 黄广慧[1] 梁波[2] 

机构地区：[1]山东大学附属省立医院东院区肿瘤科,山东济南250101 [2]山东大学附属省立医院超声影像科,山东济南250021

出　　处：《医学影像学杂志》2012年第10期1692-1695,共4页Journal of Medical Imaging

摘　　要：目的探讨微波消融联合肝动脉栓塞化疗术(TACE)治疗原发性肝癌(PHC)的临床疗效。方法 82例PHC患者随机分为两组,单纯TACE组36例(对照组),微波消融+TACE 46例(治疗组)。观察两组治疗后3个月的临床疗效和AFP变化情况及1、2、3年生存率。结果对照组和治疗组AFP由治疗前的(479.3±96.2)μg/L和(491.2±103.1)μg/L降为治疗后的(115.3±49.3)μg/L和(78.1±38.9)μg/L。1、2、3年生存率:治疗组为78.3%、54.3%、34.8%;对照组为61.1%、36.1%、19.4%。治疗组未发生严重并发症。结论微波消融联合TACE是治疗PHC的一种新的安全有效的治疗方法,可以延长PHC患者的生存期。Objective To explore the clinical effect of microwave ablation combined with transcatheter arterial chemoembolization （TACE） in treatment of primary hepatocellular carcinoma （PHC）. Methods A total of 82 patients with PHC were randomly divided into two groups： TACE group comprised 36 patients （control group）, and the other 46 were treated with combination of microwave ablation plus TACE （treatment group）. Three months after treatment, the changes in the AFP level and tumor size were analyzed. The 1-, 2-, and 3-year survival rates were calculated with Kaplan-Meier method and compared between the two groups. Results AFP in control and treatment groups droped from pre-treatment （479.3±96.2） ug/L and （491.2±103.1）ug/L reduced to the after treatment （115.3±49.3）ug/L and （78.1±38.9）ug/ L. The 1-, 2-, and 3-year survival rates were 78.3%, 54.3%, 34.8% in treatment group, and 61.1% , 36.1%, 19.4% in control group respectively （ P 〈0.01）. The treatment group did not come up with serious complication. Conclusion Compared with TACE alone, microwave ablation combined with TACE is safe and effective in treating PHC, and can achieve better results in decreasing the AFP level and improving survival rates.

关 键 词：癌 肝细胞 栓塞 治疗性 微波消融 

分 类 号：R735.7[医药卫生—肿瘤] R815[医药卫生—临床医学]